Borghaei, H., Paz-Ares, L. G., Reck, M., Herbst, R. S., Peters, S., Bhatt, K., Wang, X., Gable, J., Connor-Ahmad, S., Mamolo, C., Lin, Y., Liu, S. V. (2026). IMforte: Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of first-line maintenance (1Lm) treatment (Tx) with lurbinectedin (lurbi) + atezolizumab (atezo) vs atezo in extensive-stage small cell lung cancer (ES-SCLC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8086